Few adult haemangiomas of larynx have been reported. Most common presentations are in infants where the incidence is about 4% -5% [1] . In children they resolve by age of five whereas in adults they do not regress. In children the most common modality of treatment is by propranolol. In adults, there are various modalities of surgical excision by laser excision with Co 2 or KTP and electrocautery assisted excision. We are presenting a case of adult laryngeal haemangioma that presented with blood-tinged sputum on coughing since 8 months and we managed with micro laryngeal surgical excision by coblation without any complications.
Introduction
Benign neoplasms of larynx are infrequent, about 95% neoplasms are papillomas and remaining 5% are comprised of oncocytic tumors, pleomorphic adenoma, lymphangiomas, neurofibromas, fibromatosis, paragangliomas, rhabdomyomas and haemangiomas [2] . Haemangiomas of larynx are rare. Symptoms associated with this benign tumour are not diagnostic and mostly are related to the obstruction caused by the neoplasm. Patients may present with dysphonia, dyspnea, and dysphagia. Most of the time (in 80% cases) supraglottic region is involved, followed by glottis and sub glottis. A thorough history and complete examination are imperative for diagnosis; however, it must be confirmed by radiological imaging and biopsy. Although a biopsy would result in bleeding, differentiating a benign from malignant neoplasm is crucial, as the latter is associated with significant morbidity and mortality [2] . In this case report, we present 
Case Report
A 23-year-old male patient presented to our department with complaints of blood-tinged sputum on coughing since 8 months. There was no complaint of hoarseness of voice, difficulty in swallowing or noisy breathing. There was a similar episode 4 years ago, which subsided without any intervention. He is a non-smoker and non-alcoholic. On examination with 70˚ Endolaryngoscope, a bluish red lobular mass was visible in the interarytenoid area of larynx. 
Discussion
Adult haemangioma of larynx is a rare diagnosis. Pathogenesis is pertinent to imbalance of positive and negative angiogenic factors culminating in proliferation of the haemangioma [3] . Involution is common by the first five months of life in infants [4] . Cavernous haemangioma differ from capillary haemangioma by having large vascular channels, less well circumscribed and usually deeper in submucosal tissues [5] .
Laryngeal Haemangiomas are diagnosed primarily by history, local examination and by radiological investigations. The phonation sign of Menzel, which consists of increased firmness, erection and deepening color of the growth during phonation may be of diagnostic value [6] . patients with supraglottic haemangioma with CO 2 laser [7] . We have treated our case using Coblation technique without any complications. Biopsy was avoided in this case for it could have caused bleeding during the surgery and since we were using the Coblation for the first time in Haemangioma Larynx we were more cautious. The case was reviewed after one week and tracheostomy was de-canulated. There was no difficulty to breath or any hemoptysis in the postoperative period. Case was followed every fifteen days and endolaryngoscopy was done to rule out any recurrence. Post operatively there is no recurrence of the lesion up to date. This modality of treatment is very beneficial in usage and postoperative scarring of tissue is very minimal with quick healing and good functionality of larynx post operatively. More number of cases would be required to conclude the efficacy of Coblation.
In literature search there is no paper published for the excision of haemangioma using Coblation, which makes our case report to be first.
Conclusion
Coblation proves to be a newer modality of treatment in various laryngeal lesions; basic advantage over other modalities eases usage and also availability.
More cases need to be done to know the efficacy of coblation over other modalities in the surgical management of laryngeal haemangiomas.
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